Studies have shown that patients treated with Levemir experienced little or no weight gain compared to other basal insulin therapy, such as NPH (Neutral Protamine Hagedorn) insulin, and offers more predictable control of blood glucose levels and reduced risk of hypoglycemia particularly during the night.
“Clinical studies have shown that patients taking Levemir for type 1 or type 2 diabetes, experienced significantly less weight gain than those taking traditional human insulins and in many cases even experienced weight loss,” said Dr. Robert Schlosser, Endocrinologist and Co-Director, Lifestyle Metabolism Centre, Toronto. “The flat and predictable profile of the new basal insulin Levemir may, at least in part, explain why people lose weight or do not gain as much weight on Levemir as they do on traditional human basal insulins.”
Study results suggest that Levemir can be used in people with type 2 diabetes without causing weight gain to the degree that typically accompanies this progression of therapy. Furthermore, recent data suggest that the more overweight a patient is before insulin therapy, the less weight they will tend to gain when taking Levemir, compared to human basal insulin.
Levemir has shown a weight-sparing effect compared with other basal insulin (such as NPH) when used either in type 1 or type 2 patients.
New Data Shows That the Unique Levemir Weight Benefit Continues After Two Years of Treatment
At the same time Levemir provides significantly improved glycaemic control and reduced rates of hypoglycaemia
AMSTERDAM, Netherlands, Sept. 21, 2007– – New data from two studies announced today by Novo Nordisk at the European Association for the Study of Diabetes (EASD) meeting confirms that Levemir® (insulin detemir [rDNA origin] injection) results in less weight gain than other basal insulins in type 1 and type 2 diabetes. The studies also demonstrate that Levemir® provides good glycaemic control in both types of diabetes and reduced rates of hypoglycaemia.1,2
In a two-year study in type 1 diabetes, patients treated with Levemir® gained significantly less weight than those on NPH insulin and at the same time had significantly improved glycaemic control compared with those on NPH insulin.1 This first long-term study with a modern basal insulin versus the older and commonly used NPH insulin demonstrates that the weight advantage of Levemir® is sustainable, while simultaneously providing significantly better glycaemic control and reduced nocturnal hypoglycaemia.
The benefits of Levemir® are further confirmed in the large randomised clinical trial PREDICTIVE® 303, involving more than 5,000 patients. Type 2 diabetes patients who were switched from NPH insulin or insulin glargine to Levemir® over a period of 26 weeks actually lost weight, while still experiencing significant improvements in glycaemic control and reduced rates of hypoglycemia.2
“The fact that Levemir® provides better glycaemic control, less nocturnal hypoglycaemia and less weight gain relative to NPH insulin over a period of two years is a clinical confirmation of the superior action profile of Levemir®,” commented Professor Luigi Meneghini, associate director at the Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida.
“Further to the weight benefit, the data presented at EASD highlights that Levemir® is associated with significantly less weight gain in both type 1 and 2 diabetes, and that this benefit is maintained over time. Levemir® may therefore be a more acceptable basal insulin option for patients with diabetes who are concerned about treatment-associated weight gain.”
The findings on weight gain reported at EASD are consistent with the unique weight benefit associated with Levemir® observed in 13 out of 13 published clinical studies, in which it has been compared to other basal insulins such as insulin glargine and NPH insulin.3–15 Together these studies provide data on over 4,000 patients with diabetes.